Eli Lilly and Company has received FDA approval for Foundayo™ (orforglipron), a novel oral GLP-1 medication designed for weight loss in adults with obesity or overweight-related medical issues. Unlike other GLP-1 therapies, Foundayo can be taken at any time of day without restrictions on food or water intake. Clinical trials, particularly the ATTAIN-1 study, demonstrated that participants using the highest dose of Foundayo lost an average of 27.3 pounds, or 12.4% of their body weight, significantly outperforming the placebo group.

This development is significant for the longevity and healthspan fields as it addresses a critical need for accessible and effective obesity treatments. With less than 10% of eligible individuals currently utilizing GLP-1 medications, Foundayo’s convenient oral administration could help reduce barriers to treatment, such as stigma and complexity. Beyond weight loss, the ATTAIN studies indicate that Foundayo also leads to improvements in cardiovascular risk markers, which is crucial given the association between obesity and various age-related diseases.

The introduction of Foundayo may reshape the landscape of obesity management by providing a practical solution for patients struggling with weight loss and its associated health complications. As Lilly plans to expand availability through retail pharmacies and telemedicine providers, the potential for Foundayo to enhance patient adherence and outcomes in real-world settings is notable.

For longevity professionals, the key takeaway is that Foundayo represents a promising addition to the therapeutic arsenal against obesity, with implications for both individual health outcomes and broader public health strategies in managing age-related conditions linked to excess weight.

Source: investor.lilly.com